Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-Positive NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02336451
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
Novartis Pharmaceuticals 156
Testing effectiveness (Phase 2)Looking for participantsNCT07415005
What this trial is testing

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05987956
What this trial is testing

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Who this might be right for
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair 600
Testing effectiveness (Phase 2)Study completedNCT02040870
What this trial is testing

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 103
Testing effectiveness (Phase 2)Ended earlyNCT03737994
What this trial is testing

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI) 10
Not applicableNot Yet RecruitingNCT06652555
What this trial is testing

The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

Who this might be right for
ALKNSCLC
Shanghai Pulmonary Hospital, Shanghai, China 100
Early research (Phase 1)Study completedNCT02422589
What this trial is testing

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Who this might be right for
ALK-positive Advanced Tumors
Novartis Pharmaceuticals 33
Not applicableStudy completedNCT04979988
What this trial is testing

Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

Who this might be right for
ALK-positive Non-small-cell Lung Cancer
Pfizer 51
Not applicableStudy completedNCT03546894
What this trial is testing

Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Who this might be right for
Anaplastic Lymphoma Kinase-positiveCarcinoma Non-small-cell Lung
Takeda 111
Testing effectiveness (Phase 2)Study completedNCT02094573
What this trial is testing

Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Ariad Pharmaceuticals 222
Not applicableLooking for participantsNCT07696832
What this trial is testing

Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

Who this might be right for
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLCEGFR Mutation-negative and ALK Rearrangement-negativeEastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2+2 more
Guangdong Association of Clinical Trials
Early research (Phase 1)Looking for participantsNCT07784959
What this trial is testing

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Who this might be right for
ALK PositiveALK Positive Non-small Cell Lung CancerNSCLC+1 more
Nuvectis Pharma, Inc. 54
Testing effectiveness (Phase 2)UnknownNCT05801107
What this trial is testing

Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 30
Large-scale testing (Phase 3)UnknownNCT04009317
What this trial is testing

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 260
Early research (Phase 1)Looking for participantsNCT07617337
What this trial is testing

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Chugai Pharmaceutical 102
Early research (Phase 1)Looking for participantsNCT06225427
What this trial is testing

Gilteritinib for the Treatment of ALK NSCLC

Who this might be right for
Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
University of Michigan Rogel Cancer Center 30
Not applicableStudy completedNCT03727477
What this trial is testing

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

Who this might be right for
Non-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive
Intergroupe Francophone de Cancerologie Thoracique 291
Testing effectiveness (Phase 2)Ended earlyNCT03131206
What this trial is testing

Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Who this might be right for
ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer
Dana-Farber Cancer Institute 5
Not applicableStudy completedNCT06339554
What this trial is testing

Alectinib-induced Endocrine Toxicity

Who this might be right for
NSCLC Stage IV
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 98
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Next Page
265